Alex Nixon on Muck Rack

Alex Nixon

  • Senior Research Analyst, UPMC Enterprises, Freelance
Pittsburgh
As seen in: MLive, Pittsburgh Tribune-Review, Towards Data Science, TRIB Live, Valley News Dispatch, Duluth News Tribune, Bristol Herald Courier, Dothan Eagle, The Bradford Era, Cyber Uncut and
Senior research analyst, @UPMCEnterprises and @connectedmed #UPMCInnovates #digitalhealth Former health care journalist
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alex

Contact Alex, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Clinical Trials at the Summit 2026: First-time data, AI, and the next generation of retinal treatments

|
By Ian C. Han, Alex Nixon, Arshad Khanani
| Modern Retina
When Arshad M. Khanani, MD, MA, FASRS, founded Clinical Trials at the Summit (CTS) 6 years ago, the vision was to bring all stakeholders in retinal drug development together under one roof. At this year's meeting, to be held June 12-13 in Las Vegas, Nevada, that vision is more fully realized than ever. Khanani, who serves as meeting founder and co-chair, offered a preview of what attendees can expect during the day-and-a-half program.
Open in Who Shared Issue with article?

FDA approves ranibizumab-hkdz as first interchangeable biosimilar ranibizumab available in both vials and prefilled syringes

|
By Ian C. Han, Alex Nixon, Lucia Valentina Gambuzza
| Modern Retina
The FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited), a biosimilar referencing ranibizumab (Lucentis; Genentech), developed by Lupin Limited. Notably, ranibizumab-hkdz carries an interchangeable biosimilar designation and is the only FDA-approved ranibizumab biosimilar available in both vial and prefilled syringe (PFS) presentations—a distinction that may carry practical implications for ophthalmology practices managing high-volume intravitreal injection programs.
Open in Who Shared Issue with article?

Q&A: Peripheral vision IOL's influence on driving performance

|
By Ian C. Han, Alex Nixon, Sara Aissati
| Modern Retina
As cataract surgery continues to deliver excellent restoration of central visual acuity, a growing body of evidence suggests that the story doesn't end at the fovea. Pseudophakic eyes are known to exhibit increased peripheral refractive errors compared with phakic eyes—errors that can degrade contrast sensitivity, motion perception, and hazard detection at the eccentricities most relevant to real-world activities like driving.
Open in Who Shared Issue with article?
See all 755 licensed articles (756 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified